About CRISPR Therapeutics
CRISPR Therapeutics is a company based in Basel (Switzerland) founded in 2013.. CRISPR Therapeutics has raised $127 million across 9 funding rounds from investors including Vertex Pharmaceuticals, New Leaf Venture Partners and Franklin Templeton. The company has 393 employees as of December 31, 2024. CRISPR Therapeutics offers products and services including CASGEVY. CRISPR Therapeutics operates in a competitive market with competitors including Alnylam, Editas Medicine, Poseida Therapeutics, Ultragenyx and Senti Biosciences, among others.
- Headquarter Basel, Switzerland
- Employees 393 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Crispr Therapeutics Ag
-
Annual Revenue
$37.31 M-89.95as on Dec 31, 2024
-
Net Profit
$-366.25 M-138.43as on Dec 31, 2024
-
EBITDA
$-447.31 M-120.67as on Dec 31, 2024
-
Total Equity Funding
$127 M (USD)
in 9 rounds
-
Latest Funding Round
-
Investors
Vertex Pharmaceuticals
& 11 more
-
Employee Count
393
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CRISPR Therapeutics
CRISPR Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CRSP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CRISPR Therapeutics
CRISPR Therapeutics offers a comprehensive portfolio of products and services, including CASGEVY. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for sickle cell disease and beta thalassemia using gene editing.
Unlock access to complete
Unlock access to complete
Funding Insights of CRISPR Therapeutics
CRISPR Therapeutics has successfully raised a total of $127M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Last Round
-
First Round
First Round
(24 Apr 2014)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Post-IPO - CRISPR Therapeutics | Valuation |
investors |
|
| Apr, 2021 | Amount | Post-IPO - CRISPR Therapeutics | Valuation |
investors |
|
| Dec, 2020 | Amount | Post-IPO - CRISPR Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CRISPR Therapeutics
CRISPR Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Vertex Pharmaceuticals, New Leaf Venture Partners and Franklin Templeton. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life sciences sector
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CRISPR Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CRISPR Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Crispr Therapeutics Comparisons
Competitors of CRISPR Therapeutics
CRISPR Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Editas Medicine, Poseida Therapeutics, Ultragenyx and Senti Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Crispr Therapeutics
Frequently Asked Questions about CRISPR Therapeutics
When was CRISPR Therapeutics founded?
CRISPR Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is CRISPR Therapeutics located?
CRISPR Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Is CRISPR Therapeutics a funded company?
CRISPR Therapeutics is a funded company, having raised a total of $127M across 9 funding rounds to date.
How many employees does CRISPR Therapeutics have?
As of Dec 31, 2024, the latest employee count at CRISPR Therapeutics is 393.
What is the annual revenue of CRISPR Therapeutics?
Annual revenue of CRISPR Therapeutics is $37.31M as on Dec 31, 2024.
What does CRISPR Therapeutics do?
CRISPR Therapeutics was founded in 2013 and is headquartered in Basel, Switzerland. Operations center on the biotechnology sector, where gene-editing tools like CRISPR-Cas9 are applied to create therapies for hemoglobinopathies, cancer, and regenerative medicine. Focus is placed on translating this technology into treatments for serious genetic conditions, with activities spanning research and development in human disease solutions.
Who are the top competitors of CRISPR Therapeutics?
CRISPR Therapeutics's top competitors include Alnylam, Senti Biosciences and BioMarin Pharmaceutical.
What products or services does CRISPR Therapeutics offer?
CRISPR Therapeutics offers CASGEVY.
Is CRISPR Therapeutics publicly traded?
Yes, CRISPR Therapeutics is publicly traded on NASDAQ under the ticker symbol CRSP.
Who are CRISPR Therapeutics's investors?
CRISPR Therapeutics has 12 investors. Key investors include Vertex Pharmaceuticals, New Leaf Venture Partners, Franklin Templeton, Jefferies, and Celgene.
What is CRISPR Therapeutics's ticker symbol?
The ticker symbol of CRISPR Therapeutics is CRSP on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.